Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD
Article first published online: 16 DEC 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 14, pages 3565–3570, 15 July 2012
How to Cite
Mato, A. R., Svoboda, J., Feldman, T., Zielonka, T., Agress, H., Panush, D., Miller, M., Toth, P., Lizotte, P. M., Nasta, S., Goldberg, S., Chong, E., Schuster, S., Pecora, A. L. and Goy, A. (2012), Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer, 118: 3565–3570. doi: 10.1002/cncr.26731
- Issue published online: 2 JUL 2012
- Article first published online: 16 DEC 2011
- Manuscript Accepted: 11 OCT 2011
- Manuscript Revised: 17 SEP 2011
- Manuscript Received: 9 JUN 2011
- mantle cell lymphoma;
- positron emission tomography;
- computed tomography;
- non-Hodgkin lymphoma
Although convincing data exist regarding the prognostic utility of positron emission tomographic (PET)-computed tomographic (CT) imaging in Hodgkin lymphoma and diffuse large B-cell lymphoma, its prognostic utility both during treatment and immediately after treatment have not been systematically evaluated in a large mantle cell lymphoma (MCL) patient cohort to support its use in clinical practice.
The authors conducted a retrospective cohort study to examine the prognostic utility of PET-CT imaging in a uniform MCL patient cohort undergoing dose-intensive chemotherapy (R-HyCVAD) in the frontline setting. The primary study endpoints were progression-free survival (PFS) and overall survival (OS). PET-CT images were centrally reviewed for the purposes of this study using standardized response criteria.
Fifty-three patients with advanced stage MCL with PET-CT data were identified. With median follow-up of 32 months, 3-year PFS and OS estimates were 76% (95% confidence interval [CI], 64%-84%) and 84% (95% CI, 72%-90%), respectively. Interim PET-CT status was not associated with PFS (hazard ratio [HR], 0.9; 95% CI, 0.3-2.7; P = .8) or OS (HR, 0.6; 95% CI, 0.1-2.9; P = .5). Post-treatment PET-CT status was statistically significantly associated with PFS (HR, 5.2; 95% CI, 2.0-13.6; P = .001) and trended toward significant for OS (HR, 2.8; 95% CI, 0.8-9.6; P = .07).
These data do not support the prognostic utility of PET-CT in pretreatment and interim treatment settings. A positive PET-CT after the completion of therapy identifies a patient subset with an inferior PFS and a trend toward inferior OS. Cancer 2012;3565–3570. © 2011 American Cancer Society.